490 related articles for article (PubMed ID: 33255854)
1. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
3. The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
Hottenrott T; Schorb E; Fritsch K; Dersch R; Berger B; Huzly D; Rauer S; Tebartz van Elst L; Endres D; Stich O
J Neurol; 2018 May; 265(5):1106-1114. PubMed ID: 29511863
[TBL] [Abstract][Full Text] [Related]
4. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
5. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
Front Neurol; 2019; 10():280. PubMed ID: 30972011
[No Abstract] [Full Text] [Related]
6. The MRZ reaction in primary progressive multiple sclerosis.
Hottenrott T; Dersch R; Berger B; Rauer S; Huzly D; Stich O
Fluids Barriers CNS; 2017 Feb; 14(1):2. PubMed ID: 28166789
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
[TBL] [Abstract][Full Text] [Related]
8. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
[TBL] [Abstract][Full Text] [Related]
9. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
Front Neurol; 2020; 11():608. PubMed ID: 32765393
[No Abstract] [Full Text] [Related]
10. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
Jarius S; Eichhorn P; Franciotta D; Petereit HF; Akman-Demir G; Wick M; Wildemann B
J Neurol; 2017 Mar; 264(3):453-466. PubMed ID: 28005176
[TBL] [Abstract][Full Text] [Related]
11. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
[TBL] [Abstract][Full Text] [Related]
12. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
13. Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis.
Huss A; Mojib-Yezdani F; Bachhuber F; Fangerau T; Lewerenz J; Otto M; Tumani H; Senel M
Clin Chim Acta; 2019 Nov; 498():148-153. PubMed ID: 31437445
[TBL] [Abstract][Full Text] [Related]
14. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome.
Brettschneider J; Tumani H; Kiechle U; Muche R; Richards G; Lehmensiek V; Ludolph AC; Otto M
PLoS One; 2009 Nov; 4(11):e7638. PubMed ID: 19890384
[TBL] [Abstract][Full Text] [Related]
15. The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.
Hottenrott T; Dersch R; Berger B; Endres D; Huzly D; Thiel J; Rauer S; Stich O; Salzer U; Venhoff N
BMC Neurol; 2018 Jan; 18(1):14. PubMed ID: 29386006
[TBL] [Abstract][Full Text] [Related]
16. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
Front Neurol; 2019; 10():1008. PubMed ID: 31608004
[No Abstract] [Full Text] [Related]
17. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
18. The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?
Jarius S; Eichhorn P; Jacobi C; Wildemann B; Wick M; Voltz R
J Neurol Sci; 2009 May; 280(1-2):98-100. PubMed ID: 19041103
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
[TBL] [Abstract][Full Text] [Related]
20. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
